Clinical Trial

RT-310 Safety and Feasibility BPH Study

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-24.
Status change: Recruiting → Active, Not Recruiting 2026-03-18
Trial Details
NCT Number NCT07264205
Lead Sponsor Resurge Therapeutics Inc.
Conditions BPH (Benign Prostatic Hyperplasia)
Enrollment 20 participants
Start Date 2025-03-13
Primary Completion 2026-03 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-20